An open-label, phase I/II trial to determine the maximum tolerated dose and investigate safety, pharmacokinetics and efficacy of BI 836858, an unconjugated anti-CD33 monoclonal antibody, in combination with decitabine in patients with acute myeloid leukemia
Related Research units
Abstract
Not available.
Bibliographical data
| Original language | English |
|---|---|
| ISSN | 0390-6078 |
| DOIs | |
| Publication status | Published - 01.12.2022 |
| PubMed | 36005556 |
|---|
